Stock 301126 HUNAN DAJIAWEIKANG PHARMACEUTICAL INDUSTRY CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd

Equities

301126

CNE1000054V3

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
10.57 CNY +5.81% Intraday chart for Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd +4.45% -18.88%
Apr. 22 Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 28 Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 119.999994 million in funding CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed the share acquisition agreement to acquire 51% stake in Shanxi Simaile Pharmaceutical Chain Co., Ltd. from Yang Jinjiang, Liu Hongming for approximately CNY 330 million.
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire Yinchuan Meihetai Pharmaceutical Chain Co., Ltd. from Xie Huiyang and Xie Xiaolong for approximately CNY 250 million.
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Implements Final Cash Dividend of A Shares for the Year 2022, Payable on June 12, 2023
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Final Cash Dividend for 2022
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Proposes Final Cash Dividend for the Year 2022
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hunan Tongjian Pharmacy to Buy 86% Stake in Local Peer For 341 Million Yuan
MT
Hunan Tongjian Pharma to Buy 86% of Local TCM Maker For 341 Million Yuan
MT
Hunan Dajiaweikang Pharma to Buy 85.7% Stake in Pharma Firm
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed a Share Transfer Agreement to acquire a 85.7143% stake in Hunan Tianjicaotang Pharmaceutical CO.,LTD. from Weng Xiaotao and Xiang Zhongyou for CNY 340 million.
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd completed the acquisition of 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng.
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng for approximately CNY 140 million.
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 21 June 2022
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. Approves Cash Dividend
CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 301126 Stock
  4. News Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd
  5. Highlights